Health‐Related Quality of Life in Patients with Lung Cancer Applying Integrative Oncology Concepts in a Certified Cancer Centre

Thronicke, Anja; Trott, Phillipp von; Kröz, Matthias; Grah, Christian; Matthes, Burkhard; Schad, Friedemann

doi:10.1155/2020/5917382

Cited by 6 publications

(10 citation statements)

References 39 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Completed EORTC QLQ-C30 questionnaires were evaluated and analyzed for the entire study cohort at T0 and T1. All EORTC QLQ-C30 scores at T0 were within the range of formerly published EORTC QLQ-C30 reference values for LC patients [ 25 ] and similar as published previously [ 14 ]. In Table 3 , the mean values for T0 and T1 for all EORTC QLQ-C30 scales and the means and IQR of the longitudinal changes for all scales were determined.…”

Section: Resultssupporting

confidence: 88%

“…In a previous real-world data (RWD) study we found, that the risk of death was reduced in patients with tumor stage IV NSCLC treated with a combination of chemotherapy and VA, compared to chemotherapy alone [ 11 ]. Only few publications so far have addressed self-reported QoL in LC patients [ 2 , 3 , 12 – 14 ]. In a further RWD study, our group has shown that LC patients, age-dependently or tumor stage-dependently report increased pain, low mood and financial difficulties at diagnosis before treatment [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…Only few publications so far have addressed self-reported QoL in LC patients [2,3,[12][13][14]. In a further RWD study, our group has shown that LC patients, age-dependently or tumor stage-dependently report increased pain, low mood and financial difficulties at diagnosis before treatment [14]. Little is known about integrative treatments including VA extracts with respect to self-reported QoL in patients with LC and in most clinical LC trials QoL is only observed as a secondary outcome parameter [15,16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Lung cancer (LC) is associated with high mortality and poor quality of life (QoL). The disease as well as oncological treatments such as radiation and chemotherapy with adverse effects can impair the QoL of patients. Add-on treatment with extracts of Viscum album L. (white-berry European mistletoe, VA) has been shown to be feasible and safe and to improve the QoL of cancer patients. The aim of this study was to analyze the changes in QoL of LC patients being treated with radiation according to oncological guidelines and add-on VA treatment in a real-world setting. Methods A real-world data study was conducted using registry data. Self-reported QoL was assessed by the evaluation of the European Organization of Research and Treatment Health-Related Quality of Life Core Questionnaire scale (EORTC QLQ-C30). Adjusted multivariate linear regression analyses were performed to analyze factors associated with changes in QoL at 12 months. Results A total of 112 primary LC patients (all stages, 92% non-small-cell lung cancer, median age 70 (ICR: 63–75)), answered the questionnaires at first diagnosis and 12 months later. Assessment of 12 months changes in QoL revealed significant improvement of 27 points for pain (p = 0.006) and 17 points for nausea/vomiting (p = 0.005) in patients who received combined radiation and VA. In addition, significant improvements of 15 to 21 points for role (p = 0.03), physical (p = 0.02), cognitive (p = 0.04), and social functioning (p = 0.04) were observed in guideline treated patients receiving no radiation but add-on VA. Conclusions Add-on VA therapy reveals supportive effects for the QoL of LC patients. Particularly in combination with radiation a significant reduction in pain and nausea/ vomiting has been observed. Trial registration The study received ethics approval and was retrospectively registered (DRKS00013335 on 27/11/2017).

show abstract

Section: Resultssupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings corroborate those of previous studies conducted in the USA and Europe showing that baseline HRQoL can serve as a prognostic indicator 28 29. These observations imply that patients with low baseline HRQoL may be more fragile and vulnerable, and may be at higher risks for financial difficulties, and were thus less likely to receive adequate antitumour treatment 17 30. Nevertheless, we could not establish associations between baseline HRQoL and response to treatment.…”

Section: Discussionsupporting

confidence: 82%

Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China

Liu

Gao

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo investigate the relationship among baseline health-related quality of life (HRQoL), early changes in HRQoL from baseline to completion of the first cycle of chemotherapy, and prognosis in patients with advanced lung cancer.DesignThis was a prospective, observational study.SettingThe study was conducted in a national cancer centre in South China.ParticipantsA total of 243 patients with chemo-naïve with advanced lung cancer were enrolled.InterventionNone.Primary and secondary outcome measuresThe Functional Assessment of Cancer Therapy-Lung was used to assess HRQoL at baseline and at the end of the first cycle of chemotherapy. The Trial Outcome Index (TOI) and Lung Cancer Scale (LCS) were calculated as predictive indicators. Response to treatment was evaluated as per the Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1. Survival data were gathered from follow-up to September 2019.ResultsPatients with 5-point or greater decreases in TOI (65% vs 48%, adjusted risk ratio (aRR)=2.19, 95% CI 1.09 to 4.41) or 2-point or greater decreases in LCS (72% vs 48%, aRR=3.29, 95% CI 1.50 to 7.22) from baseline to completion of the first cycle of chemotherapy were more likely to show stable or progressive disease than those whose HRQoL had improved. Baseline TOI ≤54 (80.0% vs 69.9%, adjusted hazard risk (aHR)=1.36, 95% CI 1.01 to 1.84) and LCS ≤21 (77.6% vs 72.5%, aHR=1.36, 95% CI 1.01 to 1.83) were associated with higher risk for death compared with TOI>54 and LCS>21. Area under the curve analysis indicated that early changes in LCS and baseline LCS scores could better predict response to treatment and overall survival than the corresponding TOI values.ConclusionsHigher pretreatment HRQoL scores could predict longer survival, while declining HRQoL values could predict unfavourable treatment outcome among patients with advanced lung cancer. The use of the LCS is recommended for the routine collection of patient-reported HRQoL.Trial registration numberNCT01914120.

show abstract

“…In the hospice phase, it is crucial to clarify the patient's individual needs because not all patients die within a few weeks. Common symptoms, fatigue, and pain affect patients' functional capacity [17][18][19][20] and the patients often suffer from psychological distress, death anxiety, the inability to cope and the fear of their condition worsening in the near future [21][22][23][24]. Cancer fatigue may be persistent and affect patient's social relationships and quality of life.…”

Section: Introductionmentioning

confidence: 99%

‘I am still valuable’ – A qualitative study of incurable cancer patients coping in hospice care

Viitala

Åstedt‐Kurki

Lehto

et al. 2023

Scandinavian Caring Sciences

View full text Add to dashboard Cite

BackgroundKnowledge of the experiences of coping in patients with incurable cancer is essential for high‐quality palliative and end‐of‐life care.Aim and ObjectiveTo describe the coping experiences of patients with incurable cancer in hospice care to better develop patient‐centred care.MethodsThe data for this qualitative study were collected through semi structured interviews, with patients with incurable cancer in hospice care (N = 20) and analysed with inductive content analysis. Ethical and organisational approvals were obtained, and the participants received both verbal and written information before consenting to participate.ResultsThe patients' coping was enhanced with their involvement in treatment‐related decisions. Valuing day‐to‐day living and coping with emotional stressors helped them accept their own life situations. Accepting their increasing fragility was enhanced by their self‐reappraisal. The patients found security in the possibility of receiving support when they needed it. Although the ordinariness of dying in hospice care settings was sometimes too much to bear, they understood dying to be a part of the natural cycle of life. They questioned the responsiveness of healthcare services because they felt that they were not always heard.Study LimitationsBecause this study was limited to a specific population of cancer patients in hospice care, the results might not be generalised to other patient groups with chronic diseases or other palliative care settings.ConclusionsThe experiences of patients in hospice care of coping with incurable cancer were reminiscent of the common coping process descriptions. Surprisingly, even though participants voiced that they had accepted their situation, dying itself was something they did not find crucial to discuss. The crucial aspects – without being in denial – dealt more with focusing on positive thinking and facing life.

show abstract

Health‐Related Quality of Life in Patients with Lung Cancer Applying Integrative Oncology Concepts in a Certified Cancer Centre

Cited by 6 publications

References 39 publications

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China

‘I am still valuable’ – A qualitative study of incurable cancer patients coping in hospice care

Contact Info

Product

Resources

About